{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["39(4)"],"submitter":["Tanihara H"],"funding":["Kowa Co., Ltd."],"pubmed_abstract":["<h4>Introduction</h4>Glaucoma is a leading cause of irreversible blindness and ripasudil was the first Rho kinase inhibitor approved as antiglaucoma medication. Here we present the final analysis of the ROCK-J study, a large-scale post-marketing surveillance study to evaluate the long-term safety and effectiveness of ripasudil in Japanese patients with glaucoma or ocular hypertension in a real-word clinical setting.<h4>Methods</h4>ROCK-J was a 24-month, prospective, open-label, observational study that included ripasudil-naïve patients with glaucoma or ocular hypertension who were initiating treatment with ripasudil according to the Japanese approved indication between June 1, 2015 and April 30, 2017. The primary safety endpoint was the incidence of adverse drug reactions (ADRs) (including"],"journal":["Advances in therapy"],"pagination":["1659-1677"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8989847"],"repository":["biostudies-literature"],"pubmed_title":["Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months."],"pmcid":["PMC8989847"],"pubmed_authors":["Kurihara Y","Tanihara H","Kanno T","Kakuda T","Sano T"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.","description":"<h4>Introduction</h4>Glaucoma is a leading cause of irreversible blindness and ripasudil was the first Rho kinase inhibitor approved as antiglaucoma medication. Here we present the final analysis of the ROCK-J study, a large-scale post-marketing surveillance study to evaluate the long-term safety and effectiveness of ripasudil in Japanese patients with glaucoma or ocular hypertension in a real-word clinical setting.<h4>Methods</h4>ROCK-J was a 24-month, prospective, open-label, observational study that included ripasudil-naïve patients with glaucoma or ocular hypertension who were initiating treatment with ripasudil according to the Japanese approved indication between June 1, 2015 and April 30, 2017. The primary safety endpoint was the incidence of adverse drug reactions (ADRs) (including","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-05T00:29:20.343Z","creation":"2025-04-05T00:29:20.343Z"},"accession":"S-EPMC8989847","cross_references":{"pubmed":["35150417"],"doi":["10.1007/s12325-021-02023-y"]}}